S&P 500   3,852.37 (+0.01%)
DOW   31,177.82 (-0.03%)
QQQ   324.17 (+0.12%)
AAPL   134.06 (+1.54%)
MSFT   224.10 (-0.11%)
FB   268.42 (+0.35%)
GOOGL   1,901.39 (+1.13%)
AMZN   3,307.18 (+1.34%)
TSLA   847.50 (-0.35%)
NVDA   530.70 (-0.74%)
BABA   261.51 (-1.50%)
CGC   33.68 (+0.15%)
GE   11.37 (-0.18%)
MU   82.80 (-0.84%)
AMD   88.60 (-0.17%)
NIO   56.38 (-2.30%)
T   28.84 (-0.41%)
F   11.27 (+3.78%)
ACB   11.46 (-0.69%)
BA   209.80 (-0.78%)
DIS   172.08 (-0.90%)
NFLX   581.56 (-0.82%)
GILD   67.42 (-0.84%)
S&P 500   3,852.37 (+0.01%)
DOW   31,177.82 (-0.03%)
QQQ   324.17 (+0.12%)
AAPL   134.06 (+1.54%)
MSFT   224.10 (-0.11%)
FB   268.42 (+0.35%)
GOOGL   1,901.39 (+1.13%)
AMZN   3,307.18 (+1.34%)
TSLA   847.50 (-0.35%)
NVDA   530.70 (-0.74%)
BABA   261.51 (-1.50%)
CGC   33.68 (+0.15%)
GE   11.37 (-0.18%)
MU   82.80 (-0.84%)
AMD   88.60 (-0.17%)
NIO   56.38 (-2.30%)
T   28.84 (-0.41%)
F   11.27 (+3.78%)
ACB   11.46 (-0.69%)
BA   209.80 (-0.78%)
DIS   172.08 (-0.90%)
NFLX   581.56 (-0.82%)
GILD   67.42 (-0.84%)
S&P 500   3,852.37 (+0.01%)
DOW   31,177.82 (-0.03%)
QQQ   324.17 (+0.12%)
AAPL   134.06 (+1.54%)
MSFT   224.10 (-0.11%)
FB   268.42 (+0.35%)
GOOGL   1,901.39 (+1.13%)
AMZN   3,307.18 (+1.34%)
TSLA   847.50 (-0.35%)
NVDA   530.70 (-0.74%)
BABA   261.51 (-1.50%)
CGC   33.68 (+0.15%)
GE   11.37 (-0.18%)
MU   82.80 (-0.84%)
AMD   88.60 (-0.17%)
NIO   56.38 (-2.30%)
T   28.84 (-0.41%)
F   11.27 (+3.78%)
ACB   11.46 (-0.69%)
BA   209.80 (-0.78%)
DIS   172.08 (-0.90%)
NFLX   581.56 (-0.82%)
GILD   67.42 (-0.84%)
S&P 500   3,852.37 (+0.01%)
DOW   31,177.82 (-0.03%)
QQQ   324.17 (+0.12%)
AAPL   134.06 (+1.54%)
MSFT   224.10 (-0.11%)
FB   268.42 (+0.35%)
GOOGL   1,901.39 (+1.13%)
AMZN   3,307.18 (+1.34%)
TSLA   847.50 (-0.35%)
NVDA   530.70 (-0.74%)
BABA   261.51 (-1.50%)
CGC   33.68 (+0.15%)
GE   11.37 (-0.18%)
MU   82.80 (-0.84%)
AMD   88.60 (-0.17%)
NIO   56.38 (-2.30%)
T   28.84 (-0.41%)
F   11.27 (+3.78%)
ACB   11.46 (-0.69%)
BA   209.80 (-0.78%)
DIS   172.08 (-0.90%)
NFLX   581.56 (-0.82%)
GILD   67.42 (-0.84%)
Log in
CVE:HLS

HLS Therapeutics Inc. (HLS.V) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume49,300 shs
Average Volume97,793 shs
Market CapitalizationC$384.86 million
P/E RatioN/A
Dividend Yield1.46%
BetaN/A
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company was incorporated in 2014 and is headquartered in Toronto, Canada.

MarketRank

Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone647-495-9000
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$65.13 million
Book ValueC$6.11 per share

Profitability

Miscellaneous

Market CapC$384.86 million
Next Earnings DateN/A
OptionableNot Optionable

Receive HLS News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











HLS Therapeutics Inc. (HLS.V) (CVE:HLS) Frequently Asked Questions

What stocks does MarketBeat like better than HLS Therapeutics Inc. (HLS.V)?

Wall Street analysts have given HLS Therapeutics Inc. (HLS.V) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but HLS Therapeutics Inc. (HLS.V) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Is HLS Therapeutics Inc. (HLS.V) a good dividend stock?

HLS Therapeutics Inc. (HLS.V) pays an annual dividend of C$0.20 per share and currently has a dividend yield of 1.46%.
View HLS Therapeutics Inc. (HLS.V)'s dividend history.

Who are some of HLS Therapeutics Inc. (HLS.V)'s key competitors?

What other stocks do shareholders of HLS Therapeutics Inc. (HLS.V) own?

Who are HLS Therapeutics Inc. (HLS.V)'s key executives?

HLS Therapeutics Inc. (HLS.V)'s management team includes the following people:
  • Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 57)
  • Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder, CEO & Director (Age 61)
  • Mr. Gilbert Godin, Pres & COO (Age 59)
  • Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 47)
  • Mr. Joseph Anthony MacLean B. Com., LL.B, Director of Corp. Devel. (Age 50)

What is HLS Therapeutics Inc. (HLS.V)'s stock symbol?

HLS Therapeutics Inc. (HLS.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HLS."

How big of a company is HLS Therapeutics Inc. (HLS.V)?

HLS Therapeutics Inc. (HLS.V) has a market capitalization of C$0.00 and generates C$65.13 million in revenue each year.

What is HLS Therapeutics Inc. (HLS.V)'s official website?

The official website for HLS Therapeutics Inc. (HLS.V) is www.hlstherapeutics.com.

How can I contact HLS Therapeutics Inc. (HLS.V)?

The company can be reached via phone at 647-495-9000.

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.